CONTEXT: Symptoms and quality of life (QOL) are critically important in hematopoietic stem cell transplantation (HSCT). However, few studies have examined these factors by transplant type among diverse cultures. OBJECTIVES: To identify and compare QOL and symptom severity and prevalence by transplant type in a diverse population having HSCT. METHODS: The M. D. Anderson Symptom Inventory Blood and Marrow Transplantation (MDASI-BMT) module measured symptom severity and its impact. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) measured QOL. RESULTS: Symptom data were collected from 164 patients at eight points (pretransplant to 100 days post-transplant) and QOL data at four times. Over time, symptom severity was significantly correlated with QOL and patients who had allogeneic transplants with myeloablative regimens showed more severe sleep disturbance and poorer QOL than patients having autologous transplants. Male patients reported less fatigue than female patients. However, ethnicity was not significant. Patients whose functional status was good had fewer of the five worst symptoms and higher QOL than patients with a poor functional status. Patients with acute graft-versus-host disease had more severe symptoms than those who did not. CONCLUSION: Type of transplant and preparative regimen are the most important aspects to consider when managing symptoms and QOL. This information is important for providing anticipatory guidance and support needed during the transplantation experience, to explore in future research the mechanisms involved in symptoms after HSCT, and to develop additional effective interventions.
CONTEXT: Symptoms and quality of life (QOL) are critically important in hematopoietic stem cell transplantation (HSCT). However, few studies have examined these factors by transplant type among diverse cultures. OBJECTIVES: To identify and compare QOL and symptom severity and prevalence by transplant type in a diverse population having HSCT. METHODS: The M. D. Anderson Symptom Inventory Blood and Marrow Transplantation (MDASI-BMT) module measured symptom severity and its impact. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) measured QOL. RESULTS: Symptom data were collected from 164 patients at eight points (pretransplant to 100 days post-transplant) and QOL data at four times. Over time, symptom severity was significantly correlated with QOL and patients who had allogeneic transplants with myeloablative regimens showed more severe sleep disturbance and poorer QOL than patients having autologous transplants. Male patients reported less fatigue than female patients. However, ethnicity was not significant. Patients whose functional status was good had fewer of the five worst symptoms and higher QOL than patients with a poor functional status. Patients with acute graft-versus-host disease had more severe symptoms than those who did not. CONCLUSION: Type of transplant and preparative regimen are the most important aspects to consider when managing symptoms and QOL. This information is important for providing anticipatory guidance and support needed during the transplantation experience, to explore in future research the mechanisms involved in symptoms after HSCT, and to develop additional effective interventions.
Authors: F Schulz-Kindermann; A Mehnert; A Scherwath; L Schirmer; B Schleimer; A R Zander; U Koch Journal: Bone Marrow Transplant Date: 2007-04-09 Impact factor: 5.483
Authors: K O Anderson; S A Giralt; T R Mendoza; J O Brown; J L Neumann; G M Mobley; X S Wang; C S Cleeland Journal: Bone Marrow Transplant Date: 2007-04-16 Impact factor: 5.483
Authors: Xin Shelley Wang; Qiuling Shi; Lori A Williams; Charles S Cleeland; Gary M Mobley; James M Reuben; Bang-Ning Lee; Sergio A Giralt Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin Journal: JAMA Date: 2004-05-19 Impact factor: 56.272
Authors: Erica Campagnaro; Rima Saliba; Sergio Giralt; Linda Roden; Floralyn Mendoza; Ana Aleman; Charles Cleeland; Donna Weber; Jane Brown; Karen O Anderson Journal: Cancer Date: 2008-04-01 Impact factor: 6.860
Authors: Anna Barata; Brian D Gonzalez; Steven K Sutton; Brent J Small; Paul B Jacobsen; Teresa Field; Hugo Fernandez; Heather Sl Jim Journal: J Health Psychol Date: 2016-04-22
Authors: T Takekiyo; K Dozono; S Nara; Y Murayama; N Minamihama; N Nakano; A Kubota; M Tokunaga; T Miyazono; S Takeuchi; Y Takatsuka; A Utsunomiya Journal: Bone Marrow Transplant Date: 2017-07-10 Impact factor: 5.483
Authors: Heather S L Jim; Bryan Evans; Jiyeon M Jeong; Brian D Gonzalez; Laura Johnston; Ashley M Nelson; Shelli Kesler; Kristin M Phillips; Anna Barata; Joseph Pidala; Oxana Palesh Journal: Biol Blood Marrow Transplant Date: 2014-04-18 Impact factor: 5.742
Authors: Gary Deng; Sergio Giralt; David J Chung; Heather Landau; Jonathan Siman; Benjamin Search; Marci Coleton; Emily Vertosick; Nathan Shapiro; Christine Chien; Xin S Wang; Barrie Cassileth; Jun J Mao Journal: Support Care Cancer Date: 2017-09-17 Impact factor: 3.603
Authors: William A Wood; Allison M Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; Bryce B Reeve Journal: Biol Blood Marrow Transplant Date: 2012-12-16 Impact factor: 5.742
Authors: Areej R El-Jawahri; Harry B Vandusen; Lara N Traeger; Joel N Fishbein; Tanya Keenan; Emily R Gallagher; Joseph A Greer; William F Pirl; Vicki A Jackson; Thomas R Spitzer; Yi-Bin A Chen; Jennifer S Temel Journal: Cancer Date: 2015-12-09 Impact factor: 6.860